Zevra Therapeutics Inc (FRA:1GDA)
€ 4.14 -0.22 (-4.95%) Market Cap: 173.41 Mil Enterprise Value: 165.56 Mil PE Ratio: 0 PB Ratio: 3.90 GF Score: 50/100

Q1 2024 Zevra Therapeutics Inc Earnings Call Transcript

May 08, 2024 / 12:00PM GMT
Release Date Price: €4.74 (+0.42%)
Operator

Good morning, everyone. Thank you for joining the Zevra Therapeutics' first quarter 2024 corporate update and financial results call. Today's call is being recorded and will be made available on the company's website following the conclusion of the call.

With that, I will now turn the call over to Nicole Ochsner, Vice President of Investor Relations and Corporate Communications at Zebra Therapeutics.

Nichol Ochsner
Zevra Therapeutics Inc - Vice President of Investor Relations & Corporate Communications

Good morning, and thank you for joining us today to review Zevra Therapeutics' progress in the first quarter of 2024, outlining our clinical advances, operational achievements and financial results.

Before we get started, let me take a moment to provide some important information. I encourage you to access the news release which was published this morning and is available in the Investor section of Zevra's website.

As we begin our call, it's important to highlight that today's discussion will include forward looking statements.

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot